Saturday, December 04, 2021 5:48:57 PM
Oragenics Announces Positive COVID-19 Challenge Study Results Evaluating Multiple Formulations of its SARS-CoV-2 Vaccine Candidate
Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company") today announced the results from its study to evaluate the immunogenicity and viral load reduction impact of its SARS-CoV-2 vaccine candidate in a hamster challenge study. The study provided preclinical data for formulations designed for both intranasal and intramuscular administration.
Both formulations generated robust immune responses and reduced the SARS-CoV-2 viral loads to undetectable levels in the nasal passages and lungs five days following a viral challenge. By contrast, hamsters in the control groups that had received saline or adjuvants alone had no detectable immune response and substantial viral loads. The vaccines delivered by intranasal and intramuscular routes generated immune responses as measured by multiple assays.
"The very positive results from this hamster challenge study fully support our further development of either the intranasal or intramuscular routes of administration, however we plan to focus on the intranasal delivery route for the Terra CoV-2 vaccine due to the relative lack of competition and anticipated advantages of intranasal vaccine delivery, such as reducing viral transmission, needle-free administration, and ease of distribution, as well as the potential for conferred mucosal immunity which is presently being studied. The findings from this second preclinical study will be a part of our Investigational New Drug filing to the U.S. Food and Drug Administration, expected to be made in the second quarter of 2022, and should facilitate advancement of the program into human clinical studies," said Frederick W. Telling, Ph.D., Executive Chairman of Oragenics.
https://finance.yahoo.com/news/oragenics-announces-positive-covid-19-130000711.html
Recent OGEN News
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 09/11/2024 11:45:36 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/05/2024 08:45:12 PM
- Oragenics, Inc. Announces Closing of Public Offering • GlobeNewswire Inc. • 09/05/2024 08:30:41 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 09/05/2024 12:26:02 PM
- Oragenics, Inc. Announces Pricing of Public Offering • GlobeNewswire Inc. • 09/04/2024 12:36:47 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/04/2024 04:15:04 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 09/03/2024 08:06:54 PM
- Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients • GlobeNewswire Inc. • 08/21/2024 12:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/21/2024 12:30:09 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 08/16/2024 08:45:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/16/2024 08:30:15 PM
- Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards • GlobeNewswire Inc. • 08/16/2024 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 12:30:38 PM
- Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range • GlobeNewswire Inc. • 08/14/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/12/2024 12:30:14 PM
- Oragenics, Inc. Announces Concussion Drug Successfully Completes FDA-Required Genotoxicity Study • GlobeNewswire Inc. • 08/12/2024 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 08:30:43 PM
- Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing • GlobeNewswire Inc. • 08/08/2024 12:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 12:30:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/22/2024 08:05:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/10/2024 12:00:30 PM
- Oragenics Improves Intranasal Drug Formulation for Treating Concussed Patients • GlobeNewswire Inc. • 07/10/2024 12:00:00 PM
- Oragenics Develops Automated Intranasal Device for Treating Concussed Patients • GlobeNewswire Inc. • 06/27/2024 12:30:40 PM
- Oragenics, Inc. Announces Closing of Public Offering • GlobeNewswire Inc. • 06/26/2024 08:47:15 PM
- Oragenics, Inc. Announces Pricing of Public Offering • GlobeNewswire Inc. • 06/25/2024 12:30:00 PM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM